Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
The discovery of induced pluripotent stem cells (iPSCs) by Shinya Yamanaka in 2006 was heralded as a major breakthrough of the decade in stem cell research. The ability to reprogram human somatic cells to a pluripotent embryonic stem cell-like state through the ectopic expression of a combination of embryonic transcription factors was greeted with great excitement by scientists and bioethicists. The reprogramming technology offers the opportunity to generate patient-specific stem cells for modeling human diseases, drug development and screening, and individualized regenerative cell therapy. However, fundamental questions have been raised regarding the molecular mechanism of iPSCs generation, a process still poorly understood by scientists. The efficiency of reprogramming of iPSCs remains low due to the effect of various barriers to reprogramming. There is also the risk of chromosomal instability and oncogenic transformation associated with the use of viral vectors, such as retrovirus and lentivirus, which deliver the reprogramming transcription factors by integration in the host cell genome. These challenges can hinder the therapeutic prospects and promise of iPSCs and their clinical applications. Consequently, extensive studies have been done to elucidate the molecular mechanism of reprogramming and novel strategies have been identified which help to improve the efficiency of reprogramming methods and overcome the safety concerns linked with iPSC generation. Distinct barriers and enhancers of reprogramming have been elucidated, and non-integrating reprogramming methods have been reported. Here, we summarize the progress and the recent advances that have been made over the last 10 years in the iPSC field, with emphasis on the molecular mechanism of reprogramming, strategies to improve the efficiency of reprogramming, characteristics and limitations of iPSCs, and the progress made in the applications of iPSCs in the field of disease modelling, drug discovery and regenerative medicine. Additionally, this study appraises the role of genomic editing technology in the generation of healthy iPSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116 · cited 8×
“The nickase (D10A mutant) and the eSpCas9 variants have both been 736 shown to substantially reduce off-targets effects while still maintaining their meticulous on-target 737 cleavage221,222, (4) Catalytically dead Cas9 (dCas9) variant is generated by mutating both domains (HNH and 738 RUvC-like)219-220. dCas9, when m…”
BackgroundInfluentialInduced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310 · cited 11×
“Nanog and Lin 28 can replace Klf4 and c-Myc respectively, and estrogen-related receptor beta (ESRRb) can replace Klf4 (Yu et al., 2007; Feng et al., 2009).”
BackgroundMethodInfluentialDNA methylation patterns and epigenetic memory
Bird, A. (2002) · Genes & Development · doi:10.1101/gad.947102 · Cited by 7,124 · cited 1×
“Promoter DNA methylation is inversely associated with gene expression (Bird, 2002).”
BackgroundThe new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Okano, M., Bell, D. W., Haber, D. A., & Li, E. (1999) · Cell · doi:10.1016/s0092-8674(00)81656-6 · Cited by 6,143 · cited 1×
“Likewise, mice lacking DNA methyltransferases remain non-viable or die within weeks (Li, Bestor & Jaenisch, 1992; Okano et al., 1999).”
BackgroundA bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Targeted mutation of the DNA methyltransferase gene results in embryonic lethality
Li, E., Bestor, T. H., & Jaenisch, R. (1992) · Cell · doi:10.1016/0092-8674(92)90611-f · Cited by 3,984
DNA methylation: roles in mammalian development
Smith, Z. D., & Meissner, A. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3354 · Cited by 3,045
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
Human induced pluripotent stem cells free of vector and transgene sequences
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I. I., & Thomson, J. A. (2009) · Science · doi:10.1126/science.1172482 · Cited by 2,386
Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins
Kim, D., Kim, C.-H., Moon, J.-I., Chung, Y.-G., Chang, M.-Y., Han, B.-S., Ko, S., Yang, E., Cha, K. Y., Lanza, R., et al. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.05.005 · Cited by 1,814
Maherali, N., Sridharan, R., Xie, W., Utikal, J., Eminli, S., Arnold, K., Stadtfeld, M., Yachechko, R., Tchieu, J., Jaenisch, R., et al. (2007) · Cell stem cell · doi:10.1016/j.stem.2007.05.014 · Cited by 1,725
Induced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525
Induced pluripotent stem cells from a spinal muscular atrophy patient
Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N. (2009) · Nature · doi:10.1038/nature07677 · Cited by 1,441
Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes
Aasen, T., Raya, A., Barrero, M. J., Garreta, E., Consiglio, A., Gonzalez, F., Vassena, R., Bilić, J., Pekarik, V., Tiscornia, G., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1503 · Cited by 1,423 · cited 1×
“Under the same culture conditions, keratinocytes reprogramme 100 times more efficiently and two times faster than fibroblasts (Aasen et al., 2008).”
BackgroundFUSAKI, N., BAN, H., NISHIYAMA, A., SAEKI, K., & HASEGAWA, M. (2009) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.85.348 · Cited by 1,411 · cited 2×
“Additionally, because they constitutively replicate, these vectors may be difficult to eliminate from the somatic cells (Fusaki et al., 2009).”
BackgroundRNA-guided gene activation by CRISPR-Cas9-based transcription factors
Perez-Pinera, P., Kocak, D. D., Vockley, C. M., Adler, A. F., Kabadi, A. M., Polstein, L. R., Thakore, P. I., Glass, K. A., Ousterout, D. G., Leong, K. W., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2600 · Cited by 1,328
Suppression of induced pluripotent stem cell generation by the p53–p21 pathway
Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K., & Yamanaka, S. (2009) · Nature · doi:10.1038/nature08235 · Cited by 1,301 · cited 4×
“Conversely, overexpression of p53 inhibitor proteins (such as SV40 large T antigen, REM2, and MDM2), increased the efficiency of reprogramming (up to 23-fold compared to OSKM alone) (Park et al., 2008a; Hong et al., 2009; Mali et al., 2008; Edel et al., 2010).”
BackgroundInfluentialDang, C. V., O’Donnell, K. A., Zeller, K. I., Nguyen, T., Osthus, R. C., & Li, F. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.014 · Cited by 1,188 · cited 1×
“c-Myc is a potent oncogene associated with apoptosis, cell proliferation, and cell cycle regulation (Dang et al., 2006; Lebofsky & Walter, 2007; Patel et al., 2004).”
BackgroundLinking the p53 tumour suppressor pathway to somatic cell reprogramming
Kawamura, T., Suzuki, J., Wang, Y. V., Menendez, S., Morera, L. B., Raya, A., Wahl, G. M., & Belmonte, J. C. I. (2009) · Nature · doi:10.1038/nature08311 · Cited by 1,115
Modelling the long QT syndrome with induced pluripotent stem cells
Itzhaki, I., Maizels, L., Huber, I., Zwi-Dantsis, L., Caspi, O., Winterstern, A., Feldman, O., Gepstein, A., Arbel, G., Hammerman, H., et al. (2011) · Nature · doi:10.1038/nature09747 · Cited by 1,049
Generation of human induced pluripotent stem cells from dermal fibroblasts
Lowry, W. E., Richter, L., Yachechko, R., Pyle, A. D., Tchieu, J., Sridharan, R., Clark, A. T., & Plath, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711983105 · Cited by 1,041 · cited 2×
“Eliminates ethical issues and religious concerns associated with ESCs use Efficiency of reprogramming is generally low (Takahashi & Yamanaka, 2006; Takahashi et al., 2007; Lowry et al., 2008; Huangfu et al., 2008b)”
BackgroundA p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity
Marión, R. M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., Fernandez-Capetillo, O., Serrano, M., & Blasco, M. A. (2009) · Nature · doi:10.1038/nature08287 · Cited by 1,028 · cited 3×
“As was mentioned in reprogramming factors–cell cycle regulating genes, p53 tumor suppressor proteins have inhibitory effects on iPSC generation by promoting senescence, apoptosis and cell cycle inhibition (Kawamura et al., 2009; Marion et al., 2009; Utikal et al., 2009b; Hong et al., 2009; Banito et al., 2009).”
BackgroundThe Ink4/Arf locus is a barrier for iPS cell reprogramming
Li, H., Collado, M., Villasante, A., Strati, K., Ortega, S., Cañamero, M., Blasco, M. A., & Serrano, M. (2009) · Nature · doi:10.1038/nature08290 · Cited by 968
A Molecular Roadmap of Reprogramming Somatic Cells into iPS Cells
Polo, J. M., Anderssen, E., Walsh, R. M., Schwarz, B. A., Nefzger, C. M., Lim, S. M., Borkent, M., Apostolou, E., Alaei, S., Cloutier, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.11.039 · Cited by 861
Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse
Stadtfeld, M., Maherali, N., Breault, D. T., & Hochedlinger, K. (2008) · Cell stem cell · doi:10.1016/j.stem.2008.02.001 · Cited by 823
A nonviral minicircle vector for deriving human iPS cells
Jia, F., Wilson, K. D., Sun, N., Gupta, D. M., Huang, M., Li, Z., Panetta, N. J., Chen, Z. Y., Robbins, R. C., Kay, M. A., et al. (2010) · Nature Methods · doi:10.1038/nmeth.1426 · Cited by 734
Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model
Kikuchi, T., Morizane, A., Doi, D., Magotani, H., Onoe, H., Hayashi, T., Mizuma, H., Takara, S., Takahashi, R., Inoue, H., et al. (2017) · Nature · doi:10.1038/nature23664 · Cited by 702 · cited 1×
“The more recent long-term study involving the application of human iPSC-derived dopaminergic neurons in primate Parkinson’s disease (PD) models at the Center for iPS Cell Research and Application, Kyoto University, Japan, reveals that human iPSCs are clinically applicable for the treatment of patients with PD (Kikuchi…”
BackgroundInduced Pluripotent Stem Cell Generation Using a Single Lentiviral Stem Cell Cassette
Sommer, C. A., Stadtfeld, M., Murphy, G. J., Hochedlinger, K., Kotton, D. N., & Mostoslavsky, G. (2009) · Stem Cells · doi:10.1634/stemcells.2008-1075 · Cited by 676 · cited 1×
“, 2010) and lentivirus (Carey et al., 2009; Sommer et al., 2009)) allowed the expression of all reprogramming factors driven by a single promoter, with the genes separated by self-cleaving peptide sequences.”
BackgroundG9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis
Feldman, N., Gerson, A., Fang, J., Li, E., Zhang, Y., Shinkai, Y., Cedar, H., & Bergman, Y. (2006) · Nature Cell Biology · doi:10.1038/ncb1353 · Cited by 651
Senescence impairs successful reprogramming to pluripotent stem cells
Banito, A., Rashid, S. T., Acosta, J. C., Li, S., Pereira, C. F., Geti, I., Pinho, S., Silva, J. C., Azuara, V., Walsh, M., et al. (2009) · Genes & Development · doi:10.1101/gad.1811609 · Cited by 642 · cited 3×
“As was mentioned in reprogramming factors–cell cycle regulating genes, p53 tumor suppressor proteins have inhibitory effects on iPSC generation by promoting senescence, apoptosis and cell cycle inhibition (Kawamura et al., 2009; Marion et al., 2009; Utikal et al., 2009b; Hong et al., 2009; Banito et al., 2009).”
BackgroundSeki, T., Yuasa, S., Oda, M., Egashira, T., Yae, K., Kusumoto, D., Nakata, H., Tohyama, S., Hashimoto, H., Kodaira, M., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.06.003 · Cited by 584
A High-Efficiency System for the Generation and Study of Human Induced Pluripotent Stem Cells
Maherali, N., Ahfeldt, T., Rigamonti, A., Utikal, J., Cowan, C., & Hochedlinger, K. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.08.003 · Cited by 563 · cited 2×
“, 2009) and keratinocytes (Maherali et al., 2008), demonstrating the universality of cellular reprogramming.”
BackgroundAdenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells
Zhou, W., & Freed, C. R. (2009) · Stem Cells · doi:10.1002/stem.201 · Cited by 538
SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
Naryshkin, N. A., Weetall, M., Dakka, A., Narasimhan, J., Zhao, X., Feng, Z., Ling, K. K. Y., Karp, G. M., Qi, H., Woll, M. G., et al. (2014) · Science · doi:10.1126/science.1250127 · Cited by 524
Deterministic direct reprogramming of somatic cells to pluripotency
Rais, Y., Zviran, A., Geula, S., Gafni, O., Chomsky, E., Viukov, S., Mansour, A. A., Caspi, I., Krupalnik, V., Zerbib, M., et al. (2013) · Nature · doi:10.1038/nature12587 · Cited by 522 · cited 2×
“DOT1L52, MBD353, RCOR254, Sirt6, and miR766 (a Sirt6 inhibitor)55 are all involved in 242 chromatin remodeling, thus affecting the efficiency of reprogramming when inhibited or overexpressed.”
Two Supporting Factors Greatly Improve the Efficiency of Human iPSC Generation
Zhao, Y., Yin, X., Qin, H., Zhu, F., Liu, H., Yang, W., Zhang, Q., Xiang, C., Hou, P., Song, Z., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.10.002 · Cited by 468 · cited 1×
“For example, the expression of undifferentiated embryonic cell transcription factor 1 (UTF1) or sal-like protein 4 (SALL4) with OSKM/OSK, improved the reprogramming efficiency (Zhao et al., 2008; Tsubooka et al., 2009).”
BackgroundThe biology of the mammalian Krüppel-like family of transcription factors
Dang, D. T., Pevsner, J., & Yang, V. W. (2000) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(00)00059-5 · Cited by 458
Wang, T., Chen, K., Zeng, X., Yang, J., Wu, Y., Shi, X., Qin, B., Zeng, L., Esteban, M. A., Pan, G., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.10.005 · Cited by 458
Guenther, M. G., Frampton, G. M., Soldner, F., Hockemeyer, D., Mitalipova, M., Jaenisch, R., & Young, R. A. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.06.015 · Cited by 456
Guha, P., Morgan, J. W., Mostoslavsky, G., Rodrigues, N. P., & Boyd, A. S. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.01.006 · Cited by 368
Gao, Y., Chen, J., Li, K., Wu, T., Huang, B., Liu, W., Kou, X., Zhang, Y., Huang, H., Jiang, Y., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.02.005 · Cited by 362 · cited 1×
“DNA methylation in iPSC reprogramming DNA methylation is an epigenetic barrier of iPSC generation (Nishino et al., 2011; Doege et al., 2012; Gao et al., 2013).”
BackgroundMali, P., Ye, Z., Hommond, H. H., Yu, X., Lin, J., Chen, G., Zou, J., & Cheng, L. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0346 · Cited by 291 · cited 1×
“Conversely, overexpression of p53 inhibitor proteins (such as SV40 large T antigen, REM2, and MDM2), increased the efficiency of reprogramming (up to 23-fold compared to OSKM alone) (Park et al., 2008a; Hong et al., 2009; Mali et al., 2008; Edel et al., 2010).”
BackgroundHuman secreted tau increases amyloid-beta production
Bright, J., Hussain, S., Dang, V., Wright, S., Cooper, B., Byun, T., Ramos, C., Singh, A., Parry, G., Stagliano, N., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.007 · Cited by 230 · cited 1×
“Indeed, several clinical drug candidates have been derived from iPSC studies and are currently in clinical trials (Bright et al., 2015; Naryshkin et al., 2014; Mullard, 2015; McNeish et al., 2015).”
BackgroundGeneration of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors
Narsinh, K. H., Jia, F., Robbins, R. C., Kay, M. A., Longaker, M. T., & Wu, J. C. (2011) · Nature Protocols · doi:10.1038/nprot.2010.173 · Cited by 214
Feeder-Free Derivation of Human Induced Pluripotent Stem Cells with Messenger RNA
Warren, L., Ni, Y., Wang, J., & Guo, X. (2012) · Scientific Reports · doi:10.1038/srep00657 · Cited by 154
Roles of Sall4 in the generation of pluripotent stem cells from blastocysts and fibroblasts
Tsubooka, N., Ichisaka, T., Okita, K., Takahashi, K., Nakagawa, M., & Yamanaka, S. (2009) · Genes to Cells · doi:10.1111/j.1365-2443.2009.01301.x · Cited by 154 · cited 1×
“For example, the expression of undifferentiated embryonic cell transcription factor 1 (UTF1) or sal-like protein 4 (SALL4) with OSKM/OSK, improved the reprogramming efficiency (Zhao et al., 2008; Tsubooka et al., 2009).”
BackgroundNakanishi, M., & Otsu, M. (2012) · Current Gene Therapy · doi:10.2174/156652312802762518 · Cited by 147
Cited by
Deinsberger, J., Reisinger, D., & Weber, B. (2020) · npj Regenerative Medicine · doi:10.1038/s41536-020-00100-4 · Cited by 158
O'Shea, O., Steeg, R., Chapman, C., Mackintosh, P., & Stacey, G. N. (2020) · Stem Cell Research · doi:10.1016/j.scr.2020.101773 · Cited by 59
Metadata
- Authors
- Omole, A. E., & Fakoya, A. O. J.
- Venue
- PeerJ
- Publisher
- PeerJ
- Published
- 2018-05-11
- Volume
- 6
- Pages
- e4370
- ISSN
- 2167-8359 (ISSN-L)
- OpenAlex
- W2765385557
- Cited by
- 204
- References
- 50
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.